Title: Lessons learned from the human genome project: The health implications of privatizing scientific research in the United States
Abstract:
Introduction: Recent policy shifts focusing on privatization and commercialization of scientific research have raised questions regarding the consequences of a profit-driven science model for public research institutions and public health infrastructure. Historically, publicly funded research has provided foundational knowledge necessary for private firms to pursue biomedical innovations, such as vaccines and drugs, that support public health and disease prevention. However, as federal institutions relinquish decades of scientific research projects, the nation is at risk of overlooking the importance of public research to the biomedical innovation pipeline and, consequentially, maintenance of current public health infrastructure. To examine this issue, my research utilizes evidence from the Human Genome Project (HGP), an effort which generated the first human genome sequence, and its competition with Celera Genomics, a private biotechnology firm, to therefore reveal the consequences of ongoing shifts toward privatization as well as the importance of past public research initiatives to public health.
Methods: This study employed a qualitative case study design in which I conducted a systematic review of HGP policy reviews, data, news articles, and research papers from the classified National Human Genome Research Institute (NHGRI) archive. Comparative analysis was conducted, analyzing the contrasting ideologies and models of the HGP and Celera respectively. Additional relevant literature was sourced from PubMed, Google Scholar, and reputable news articles in order to contextualize the case-study within broader science and health policy.
Results: The analysis revealed that foundational discoveries and subsequent health innovations of the HGP were possible due to a resulting balance promoted by the HGP’s open-science model alongside Celera’s proprietary framework. Specifically, the baseline data generated by the HGP enabled private firms, particularly Celera, to utilize this information in order to create tangible products, stimulating the bioeconomy and public health through innovation of medical technologies and diagnostics. In turn, these competitive developments in the private sector strengthened the HGP by incentivizing growth, efficiency, and free data access to promote further genomic research and innovation as a result.
Conclusion: The case study presented by the HGP and Celera illustrate that scientific innovation and public health infrastructure thrive when both the private and public sectors work together to translate public discoveries into marketable products that benefit the population’s health. However, the current research cuts and shift to privatization have disrupted this balance, severing the fundamental knowledge generated by the public sector and concentrating research and biotechnology with wealthier private firms. As a result, there may be an increase in public health disparities due to firm’s monopolies over certain innovations, causing a focus on profits rather than pure science and restricted access to knowledge through intellectual property. The lack of government oversight alongside higher costs for consumers may decreases equitable access to innovation as well as national disease preparedness and public health infrastructure. Thus, a science model based on privatization may not only limit the possibility of true biomedical innovation but will mainly harm patients who depend on medical advancements.
